Joslin Diabetes Center

Summary

Joslin Diabetes Center is a medical facility located in Boston, Massachusetts. This center is recognized for care of Diabetes, Type 1 Diabetes, Type 2 Diabetes, Obesity, Diabetic Retinopathy and other specialties. Joslin Diabetes Center is involved with conducting 169 clinical trials across 105 conditions. There are 16 research doctors associated with this hospital, such as Osama Hamdy, Jason Gaglia, Dr., Mary E Patti, MD, and Lori Laffel.

Top PIs

Clinical Trials running at Joslin Diabetes Center

Diabetes

Type 1 Diabetes

Chronic Kidney Disease

Type 2 Diabetes

Obesity

Acute Kidney Injury

Hypoglycemia

Diabetic Retinopathy

Cardiovascular Disease

Reactive Hypoglycemia

GNTI-122

for Type 1 Diabetes

This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety.

Recruiting

1 award

Phase 1

4 criteria

Hybrid Closed Loop Insulin Delivery

for Diabetes in Pregnancy

T1D Pregnancy \& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes.

Recruiting

1 award

N/A

9 criteria

HLA Genotype Study

for Type 1 Diabetes

This is a study to evaluate the HLA-DRB1\*04:01 genotype in adults that have been diagnosed with type 1 diabetes

Recruiting

1 award

N/A

3 criteria